Encodia, a San Diego protein‑sequencing company that developed a DNA‑tagging ProteoCode approach, ceased operations late last year and has begun auctioning laboratory equipment, GenomeWeb reported. The company—launched by sequencing veterans including a cofounder of Illumina—filed an assignment for the benefit of creditors in November 2025 after raising prior venture capital. Encodia’s closure underscores the commercialization risk for next‑generation protein sequencing platforms: substantial capital is required to move from prototyping to reproducible, CLIA‑grade services. The shutdown will reverberate in proteomics startups and investors evaluating the pathway to scale novel sequencing modalities.